CGEN

Compugen Ltd. (CGEN) is a pioneering clinical-stage biotechnology firm dedicated to developing innovative therapeutics for cancer and autoimmune disorders. Utilizing its advanced computational discovery platform, the company is actively advancing a diverse pipeline of immuno-oncology candidates that target critical pathways in the tumor microenvironment. Headquartered in Holon, Israel, Compugen is well-positioned to capitalize on international opportunities, particularly in the U.S. and Europe, as it seeks to transform treatment paradigms and improve patient outcomes in oncology and related therapeutic areas.